Physician profile
Donald Tsay
NPI 1962586321
$6,531.26
in general payments reported to CMS, 2019-2025
34 companies · $1,294 in 2025
The $1,294 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,123 · 2020: $122 · 2021: $369 · 2022: $702 · 2023: $1,073 · 2024: $1,849 · 2025: $1,294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,197 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,196.68 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,521.66 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $903.29 | 2022-2025 | Vraylar, Ubrelvy |
| Pfizer INC. | $587.56 | 2019-2025 | |
| Amgen INC. | $334.50 | 2019-2025 | Otezla, Repatha, Repatha |
| Novo Nordisk INC | $319.42 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $294.21 | 2019-2025 | Jardiance |
| Exact Sciences Corporation | $258.54 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $209.62 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Janssen Pharmaceuticals, INC | $172.03 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $163.91 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $139.87 | 2019-2025 | Zoryve |
| Amarin Pharma, INC. | $85.12 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $43.07 | 2025 | Givlaari |
| Glaxosmithkline, LLC. | $41.33 | 2025 | Trelegy Ellipta, Arexvy |
| Mylan Specialty L.P. | $39.97 | 2023-2024 | Yupelri |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $35.96 | 2023 | Guardian Connect |
| Biohaven Pharmaceutical Holding Company LTD. | $32.37 | 2022 | |
| Sanofi Pasteur INC. | $30.39 | 2019-2024 | |
| Grifols USA, LLC | $28.86 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.44 | 2022 | |
| Novartis Pharmaceuticals Corporation | $28.33 | 2019-2022 | |
| Neuronetics, INC. | $26.15 | 2023 | Neurostar Tms Therapy System |
| Genentech USA, INC. | $25.72 | 2019 | |
| Becton, Dickinson and Company | $24.70 | 2024 | Bd Max System, Bd Max Instrument |
| Bayer Healthcare Pharmaceuticals INC. | $19.62 | 2023 | |
| Nestle Healthcare Nutrition INC. | $16.51 | 2023 | |
| Idorsia Pharmaceuticals US INC | $16.48 | 2023 | Quviviq |
| Ibsa Pharma INC. | $16.40 | 2024 | Licart, Tirosint |
| Otsuka America Pharmaceutical, INC. | $16.29 | 2024 | Rexulti |
| Xeris Pharmaceuticals, INC. | $14.90 | 2023 | Gvoke Hypopen |
| E.R. Squibb & Sons, L.L.C. | $14.35 | 2022 | |
| Redhill Biopharma INC. | $14.27 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.87 | 2019 | |
| Gilead Sciences, INC. | $13.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Tsay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.